CClinicalTrials.gg
CompletedNCT03476356Updated Mar 26, 2018

L-Carnitine and Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome

An interventional study of oral clomiphene citrate and oral carnitine supplementation in Polycystic Ovary Syndrome, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-26.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

The purpose of the study to assess the efficacy of adding L-carnitine to clomiphene citrate for increasing the ovulation and the pregnancy rate in women with PCOS.

Read the detailed description

A total of 106 women with the diagnosis of PCOS based on the European Society of Human Reproduction and Embryology/ American Society for Reproductive Medicine (ESHRE/ASRM) guidelines criteria (Rotterdam Criteria, 2003) will be randomly assigned using a computer-generated randomization sheet and they will be distributed into two groups:

  1. Group L (53 patients):

    This group will receive oral clomiphene citrate (Clomid, Global Napi Pharmaceuticals (GNP), Egypt) (50 mg tablet, two times per day) from the third day of the cycle until the seventh day of the cycle plus oral carnitine supplementation (Carnivita Forte, Eva Pharma, Egypt) (1g tablet, three times per day) from the third day of the cycle until the day of the pregnancy test.

  2. Group C (53 patients):

This group will receive oral clomiphene citrate only (Clomid, Global Napi Pharmaceuticals (GNP), Egypt) (50 mg tablet, two times per day) from the third day of the cycle until the seventh day of the cycle. Serum FSH, LH \& free testosterone concentrations will be measured on day 3 (basal) of the cycle. Trans-vaginal folliculometry will be performed on all women on days 7 and 9 of the cycle and then individualized according to the response. When one leading follicle attains a diameter of 17mm or more, the endometrial thickness will be measured and 10,000 IU of Human chorionic gonadotropin (hCG) will be given (im injection; Pregnyl, organon, Holland). Timed intercourse will be advised after 36-48 hours from the night of hCG administration for 2 successive days. Ovulation success will be confirmed by transvaginal ultrasound which will show that the leading follicle has collapsed, and some fluid appeared in the Douglas pouch.

Serum progesterone will be measured on day 8 post hCG injection, ovulation will be confirmed if the serum progesterone level is ≥ 5 ng/ml (Leiva et al., 2015).

Luteal-phase support will not be provided in both groups. Pregnancy test will be done in the form of testing the level of beta hCG in the blood after 14 days once the success of the ovulation process has been confirmed.

02

Conditions studied

  • Polycystic Ovary Syndrome
03

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Age ranging from 18-35 years.
  2. Normal Hysterosalpingo-graphy (HSG).
  3. Normal Semen analysis of the husband.
  4. Diagnosed with PCOS based on the (ESHRE/ASRM) guidelines criteria (Rotterdam Criteria 2003).

Exclusion criteria

Exclusion Criteria:

  1. Patient's refusal.
  2. Male factors of infertility and/or abnormal HSG.
  3. Hyperprolactinemia (prolactin ≥ 22 ng/dl).
  4. FSH on day 3 > 15 mIU/mL.
  5. Gross ovarian pathology diagnosed by ultrasound.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Group L

    This group will receive oral clomiphene citrate (Clomid, Global Napi Pharmaceuticals (GNP), Egypt) (50 mg tablet, two times per day) from the third day of the cycle until the seventh day of the cycle plus oral carnitine supplementation (Carnivita Forte, Eva Pharma, Egypt) (1g tablet, three times per day) from the third day of the cycle until the day of the pregnancy test.

    Drug: oral clomiphene citrate · Drug: oral carnitine supplementation

  • Active comparator
    Group C

    This group will receive oral clomiphene citrate only (Clomid, Global Napi Pharmaceuticals (GNP), Egypt) (50 mg tablet, two times per day) from the third day of the cycle until the seventh day of the cycle.

    Drug: oral clomiphene citrate

Interventions

  • Drugoral clomiphene citrate

    oral clomiphene citrate 50 mg tablet, two times per day will be received from the third day of the cycle until the seventh day of the cycle.

    Also known as: clomid

  • Drugoral carnitine supplementation

    oral carnitine supplementation 1g tablet, three times per day will be received from the third day of the cycle until the day of the pregnancy test.

    Also known as: Carnitiva Forte

05

What researchers measure

Primary outcomes

  1. Ovulation success by trans-vaginal ultrasound

    Ovulation success will be confirmed by transvaginal ultrasound which will show that the leading follicle has collapsed, and some fluid appeared in the Douglas pouch.

    Time frame: 36-48 hours after night of hCG administration

Secondary outcomes

  1. Serum progesterone

    Serum progesterone will be measured on day 8 post hCG injection, ovulation will be confirmed if the serum progesterone level is ≥ 5 ng/ml.

    Time frame: Day 8 post hCG injection

  2. Clinical pregnancy

    Pregnancy test will be done in the form of testing the level of beta hCG in the blood after 14 days once the success of the ovulation process has been confirmed.

    Time frame: 14 days after hCG administration

06

Study locations

1 site
  • Department of obstetrics and gynaecology, faculty of medicine, Ain shams university
    Cairo, 11591, Egypt
07

References and documents

Individual participant data

Plan to share: Yes — L-Carnitine and Clomiphene Citrate for induction of ovulation in women with Polycystic Ovary Syndrome

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03476356
Lead sponsor
Ain Shams University
Responsible party
Rehab Mohamed Abdelrahman (Rehab Mohamed Abdelrahman, Ain Shams University) — Principal investigator
First posted
Mar 26, 2018
Start date
Nov 1, 2017
Primary completion
Mar 1, 2018
Completion
Mar 1, 2018
Last update
Mar 26, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion